GARBSEN, GERMANY – LPKF reported third quarter sales of €33 million ($34.9 million), an increase of 5.4% from last year's third quarter sales of €31.3 million ($33.1 million).
For the first nine months of the year, the company's sales reached €80.9 million ($85.7 million) compared to €86.8 million ($91.9 million) in the same period last year, and LPKF projects sales of €125 million to €135 million ($132.4 million to $142.9 million) for the full year.
"We are pleased with the good order development in the third quarter and are focused on managing the upcoming deliveries in the fourth quarter well", said Dr. Klaus Fiedler, CEO of LPKF. "In addition, we are pleased that the marketing campaign for the CellShepherd has started as planned. The CellShepherd is the first product from our new biotechnology product line (ARRALYZE) and will be officially launched in the first half of 2024."